Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#11 / 200 Total
RYDE - Ryde Group Ltd. - Stock Price Chart
TickerRYDE [AMEX]
CompanyRyde Group Ltd.
CountrySingapore
IndustrySoftware - Application
Market Cap104.34MEPS (ttm)-0.50
P/E-EPS this Y68.64%
Forward P/E-EPS next Y61.11%
PEG-EPS past 5Y-
P/S16.15EPS next 5Y-
P/B-EPS Q/Q-314.61%
Dividend-Sales Q/Q-33.35%
Insider Own59.60%Inst Own-
Insider Trans0.00%Inst Trans-
Short Float0.14%Earnings-
Analyst Recom1.00Target Price8.02
Avg Volume300.04K52W Range2.02 - 8.12
Ryde Group Ltd. is an emerging growth company. It operates under the Mobility and Quick Commerce segments. The Mobility segment includes providing on-demand and scheduled carpooling and ride-hailing services, matching riders to driver partners. The Quick Commerce segment focuses on on-demand, scheduled, and multi-stop parcel delivery services. The company was founded on February 21, 2023 and is headquartered in Singapore.
NNVC - NanoViricides Inc - Stock Price Chart
TickerNNVC [AMEX]
CompanyNanoViricides Inc
CountryUSA
IndustryBiotechnology
Market Cap16.49MEPS (ttm)-0.80
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y22.25%
P/S-EPS next 5Y-
P/B1.32EPS Q/Q-19.83%
Dividend-Sales Q/Q-
Insider Own4.62%Inst Own10.28%
Insider Trans0.00%Inst Trans19.17%
Short Float1.00%EarningsFeb 16/a
Analyst Recom1.00Target Price6.50
Avg Volume29.32K52W Range1.00 - 2.00
Today 06:30AM A Novel Broad-Spectrum Antiviral with Activity Against Influenza A (ACCESSWIRE) +23.89%
Apr-30-24 06:30AM NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon (ACCESSWIRE) +6.19%
Feb-15-24 06:30AM NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon (ACCESSWIRE)
Feb-14-24 05:11PM NanoViricides: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
Feb-01-24 06:20AM Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics (ACCESSWIRE)
Jan-29-24 06:30AM Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found (ACCESSWIRE) +9.35%
Jan-04-24 06:30AM NanoViricides to Present at the Biotech Showcase in San Fransisco (ACCESSWIRE) +5.83%
Nov-29-23 01:32PM NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387 (News Direct)
Nov-28-23 06:40AM The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Companys Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides (ACCESSWIRE) +13.73%
Nov-15-23 06:45AM NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications (ACCESSWIRE) -9.70%
NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.
UPLD - Upland Software Inc - Stock Price Chart
TickerUPLD [NASD]
CompanyUpland Software Inc
CountryUSA
IndustrySoftware - Application
Market Cap88.01MEPS (ttm)-4.75
P/E-EPS this Y-36.43%
Forward P/E5.02EPS next Y3.14%
PEG-EPS past 5Y-60.49%
P/S0.30EPS next 5Y-
P/B4.44EPS Q/Q23.05%
Dividend-Sales Q/Q-8.20%
Insider Own19.13%Inst Own79.41%
Insider Trans-0.65%Inst Trans2.95%
Short Float2.17%EarningsMay 02/a
Analyst Recom2.67Target Price3.50
Avg Volume546.68K52W Range1.89 - 5.28
Upland Software, Inc. engages in providing cloud-based software applications. Its products include AccuRoute, Adestra, Altify, BA Insight, Cimpl, ComSci, Eclipse PPM, FileBound, InGenius, Intelligent Capture, InterFAX, Kapost, Localytics, Mobile Commons, Objectif Lune, Panviva, PostUp, PowerStreering, PSA, Qvidian, Rant and Rave, RightAnswers, RO Innovation, Second Street, Ultriva, and Waterfall. The company was founded by John T. McDonald in July 2010 and is headquartered in Austin, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COURTER STEPHEN EDirectorNov 21 '23Sale4.4320,44890,62674,232Nov 22 03:27 PM
Doman DanChief Product OfficerNov 07 '23Sale4.8013,99667,242199,779Nov 09 04:50 PM
XELA - Exela Technologies Inc - Stock Price Chart
TickerXELA [NASD]
CompanyExela Technologies Inc
CountryUSA
IndustrySoftware - Application
Market Cap16.50MEPS (ttm)-13.60
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y72.45%
P/S0.02EPS next 5Y-
P/B-EPS Q/Q-212.15%
Dividend-Sales Q/Q-0.94%
Insider Own0.86%Inst Own11.16%
Insider Trans0.00%Inst Trans-
Short Float11.19%EarningsApr 17/a
Analyst Recom3.00Target Price400.00
Avg Volume151.03K52W Range1.83 - 8.85
Exela Technologies, Inc. engages in the provision of transaction processing solutions and enterprise information management. It operates through the following segments: Information and Transaction Processing Solutions (ITPS), Healthcare Solutions (HS), and Legal and Loss Prevention Services (LLPS). The ITPS segment is involved in the solutions and services designed to aid businesses in information capture, processing, decisioning, and distribution to customers primarily in the financial services, commercial, public sector, and legal industries. The HS segment operates and maintains a consulting and outsourcing business specializing in both the healthcare provider and payer markets. The LLPS segment offers a broad and active array of support services in connection with class action, bankruptcy labor, claims adjudication and employment, and other legal matters. The company was founded in 2004 and is headquartered in Irving, TX.
AGBA - AGBA Group Holding Limited - Stock Price Chart
TickerAGBA [NASD]
CompanyAGBA Group Holding Limited
CountryHong Kong
IndustryCapital Markets
Market Cap297.56MEPS (ttm)-0.75
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-332.18%
P/S5.49EPS next 5Y-
P/B33.90EPS Q/Q-322.41%
Dividend-Sales Q/Q-
Insider Own0.00%Inst Own0.04%
Insider Trans-Inst Trans0.47%
Short Float0.03%EarningsNov 14/b
Analyst Recom-Target Price-
Avg Volume11.32M52W Range0.32 - 4.29
AGBA Group Holding Ltd. is a wealth and health platform, which engages in the activities span a business-to-business platform, healthcare and wellness services, fintech businesses, as well as financial advisory services. It operates through the following business segments: Distribution Business, Platform Business, Fintech Business, and Healthcare Business. The Distribution Business segment facilitates the placement of insurance, investment, real estate and other financial products and services to the customers, through licensed brokers, in exchange for initial and ongoing commissions. The Platform Business segment provides access to financial products and services to licensed brokers. The Fintech Business segment focuses on the ensemble of fintech investments. The Healthcare Business segment manages an ensemble of healthcare-related investments. The company was founded in 2018 and is headquartered in Hong Kong.
LCTX - Lineage Cell Therapeutics Inc - Stock Price Chart
TickerLCTX [AMEX, RUT]
CompanyLineage Cell Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap245.44MEPS (ttm)-0.12
P/E-EPS this Y5.56%
Forward P/E-EPS next Y-9.41%
PEG-EPS past 5Y19.25%
P/S27.42EPS next 5Y-
P/B3.59EPS Q/Q25.94%
Dividend-Sales Q/Q9.03%
Insider Own0.55%Inst Own48.15%
Insider Trans-Inst Trans0.01%
Short Float5.64%EarningsMay 09/a
Analyst Recom1.50Target Price5.20
Avg Volume942.38K52W Range0.84 - 1.61
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAILEY DON MDirectorFeb 08 '24Buy1.0496,155100,001158,801Feb 08 07:00 PM
BROADWOOD PARTNERS, L.P.DirectorFeb 06 '24Buy1.046,730,7707,000,00141,666,255Feb 08 06:58 PM
Jayasuriya AnulaDirectorDec 29 '23Buy1.0910,00010,90010,000Jan 02 07:08 PM
OCGN - Ocugen Inc - Stock Price Chart
TickerOCGN [NASD]
CompanyOcugen Inc
CountryUSA
IndustryBiotechnology
Market Cap419.45MEPS (ttm)-0.27
P/E-EPS this Y5.95%
Forward P/E-EPS next Y-2.53%
PEG-EPS past 5Y41.20%
P/S297.48EPS next 5Y-
P/B10.31EPS Q/Q57.07%
Dividend-Sales Q/Q-
Insider Own2.20%Inst Own10.21%
Insider Trans0.00%Inst Trans-2.90%
Short Float17.97%EarningsMay 14/b
Analyst Recom1.00Target Price6.67
Avg Volume9.68M52W Range0.34 - 2.11
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zhang JungeDirectorJun 14 '23Buy0.50200,27899,9991,077,182Jun 16 04:22 PM
MSS - Maison Solutions Inc. - Stock Price Chart
TickerMSS [NASD]
CompanyMaison Solutions Inc.
CountryUSA
IndustryGrocery Stores
Market Cap18.03MEPS (ttm)-0.01
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.33EPS next 5Y-
P/B1.94EPS Q/Q-184.29%
Dividend-Sales Q/Q-4.02%
Insider Own95.27%Inst Own3.68%
Insider Trans0.00%Inst Trans-
Short Float30.69%Earnings-
Analyst Recom-Target Price-
Avg Volume188.97K52W Range0.68 - 22.97
Maison Solutions, Inc. operates as a holding company with interests in food retailing. It offers traditional Asian food and merchandise to U.S. consumers, in particular to members of Asian-American communities. The firm's products include meats, seafood, and Asian vegetables and fruits such as Chinese broccoli, bitter melon, winter gourd, Shanghai baby bokchoy, longan and lychee. The company was founded in July 2019 and is headquartered in Monterey Park, CA.
OM - Outset Medical Inc - Stock Price Chart
TickerOM [NASD, RUT]
CompanyOutset Medical Inc
CountryUSA
IndustryMedical Devices
Market Cap191.43MEPS (ttm)-3.49
P/E-EPS this Y22.82%
Forward P/E-EPS next Y13.86%
PEG-EPS past 5Y-15.08%
P/S1.47EPS next 5Y-
P/B1.55EPS Q/Q10.34%
Dividend-Sales Q/Q-4.69%
Insider Own8.20%Inst Own106.59%
Insider Trans-2.27%Inst Trans-4.76%
Short Float18.51%EarningsMay 08/a
Analyst Recom2.25Target Price5.79
Avg Volume968.42K52W Range1.92 - 24.13
Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nash MarcSVP Operations and R&DMar 15 '24Sale2.132,3915,093242,510Mar 15 06:40 PM
Ahmed NabeelChief Financial OfficerMar 01 '24Sale3.151,5844,990322,877Mar 04 04:34 PM
Trigg LeslieChair and CEOFeb 15 '24Sale3.575,32018,992833,091Feb 16 05:29 PM
Ahmed NabeelChief Financial OfficerFeb 15 '24Sale3.574,40315,719312,594Feb 16 05:24 PM
Brottem John L.General CounselFeb 15 '24Sale3.573,34111,927245,046Feb 16 05:26 PM
VRM - Vroom Inc. - Stock Price Chart
TickerVRM [NASD]
CompanyVroom Inc.
CountryUSA
IndustryAuto & Truck Dealerships
Market Cap27.70MEPS (ttm)-209.42
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-26.07%
P/S0.03EPS next 5Y-
P/B0.23EPS Q/Q-695.64%
Dividend-Sales Q/Q12.69%
Insider Own14.23%Inst Own21.72%
Insider Trans-18.44%Inst Trans-92.42%
Short Float21.37%EarningsMay 09/a
Analyst Recom3.00Target Price80.00
Avg Volume170.46K52W Range8.11 - 225.60
Apr-28-24 09:04AM 15 Best Used Car Websites in USA (Insider Monkey)
Apr-24-24 02:15PM Vroom CEO says shutting down its online used-car business was 'gut-wrenching' (TheStreet)
Apr-23-24 04:15PM Vroom to Release First Quarter 2024 Earnings on May 9, 2024 (Business Wire) +5.44%
Mar-13-24 04:32PM Vroom: Q4 Earnings Snapshot (Associated Press Finance) +53.83%
04:05PM Vroom Announces Fourth Quarter and Full Year 2023 Results (Business Wire)
Feb-23-24 02:52PM Why Is Vroom (VRM) Stock Up 25% Today? (InvestorPlace) +18.88%
Feb-22-24 04:15PM Vroom to Release Fourth Quarter and Fiscal Year 2023 Earnings on March 13, 2024 (Business Wire) -15.03%
Feb-01-24 02:12PM Vroom laying off 515 workers in Texas, part of nationwide restructuring (FreightWaves)
Jan-25-24 08:21AM Vroom (VRM) Discontinues E-commerce Used Vehicle Operations (Zacks)
Jan-23-24 10:30AM Vroom, Lockheed Martin, Fisker: Trending Tickers (Yahoo Finance Video) -42.38%
Vroom, Inc. engages in providing an ecommerce platform for the buying and selling of used vehicles. The company operates through the following segments: Ecommerce, Texas Direct Auto (TDA) and Wholesale. The Ecommerce segment represents retail sales of used vehicles through its ecommerce platform and fees earned on sales of value-added products associated with those vehicles sales. The TDA segment handles retail sales of used vehicles from TDA and fees earned on sales of value-added products associated with those vehicles sales. The Wholesale segment is involved in sales of used vehicles through wholesale auctions. The company was founded in 2012 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moran PatriciaCLO & SecretaryApr 03 '24Sale12.235871010,787Apr 05 06:14 PM
Stott Carol DeniseChief People & Culture OfficerApr 03 '24Sale12.23354289,459Apr 05 06:13 PM
Zakowicz AgnieszkaPrincipal Accounting OfficerApr 03 '24Sale12.235614,905Apr 05 06:14 PM
Moran PatriciaCLO & SecretaryFeb 06 '24Sale0.2110,7922,311827,666Feb 08 05:03 PM
Shortt Thomas HChief Executive OfficerJan 05 '24Sale0.5447,03025,2833,172,839Jan 09 04:30 PM
12345671020